Literature DB >> 23375850

The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).

Jan N Basile1.   

Abstract

Type 2 diabetes mellitus (T2DM) significantly increases morbidity and mortality from cardiovascular disease (CVD). Treatments for patients with T2DM have the potential to reduce cardiovascular (CV) risk. This review focuses on the potential of a new class of antidiabetic agents, the sodium glucose cotransporter 2 (SGLT2) inhibitors, to reduce CV risk in patients with T2DM through reductions in hyperglycemia, blood pressure (BP), and body weight. The results of clinical trials of SGLT2 inhibitors are summarized and discussed.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23375850     DOI： 10.1016/j.jdiacomp.2012.12.004

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN： 1056-8727            Impact factor:   2.852


  15 in total

Review 1.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Diabetologia       Date:  2016-11-22       Impact factor: 10.122

Review 2.  Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

3.  Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Authors:  Martin Ridderstråle; Robbyna Svaerd; Cordula Zeller; Gabriel Kim; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-09-05       Impact factor: 9.951

Review 4.  The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.

Authors:  S A Brunton
Journal:  Int J Clin Pract       Date:  2015-07-05       Impact factor: 2.503

Review 5.  Targeting glucose metabolism for healthy aging.

Authors:  Rachel A Brewer; Victoria K Gibbs; Daniel L Smith
Journal:  Nutr Healthy Aging       Date:  2016-10-27

6.  Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.

Authors:  J Rosenstock; A Jelaska; C Zeller; G Kim; U C Broedl; H J Woerle
Journal:  Diabetes Obes Metab       Date:  2015-07-14       Impact factor: 6.577

7.  Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus.

Authors:  Harold Bays
Journal:  Diabetes Ther       Date:  2013-10-19       Impact factor: 2.945

Review 8.  Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.

Authors:  Michael A Nauck
Journal:  Drug Des Devel Ther       Date:  2014-09-11       Impact factor: 4.162

Review 9.  SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.

Authors:  Jochen Seufert
Journal:  Diabetes Metab Syndr Obes       Date:  2015-11-09       Impact factor: 3.168

Review 10.  SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Authors:  Naveed Sattar; James McLaren; Søren L Kristensen; David Preiss; John J McMurray
Journal:  Diabetologia       Date:  2016-04-25       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.